Processa Pharmaceuticals Inc. (PCSA) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 55.7 (BULLISH MOMENTUM)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While PCSA currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.85) and Max Pain ($1.98) forces dealer call-delta covering toward $10.76.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Processa Pharmaceuticals Inc. (PCSA) surged +2.16% to $1.89, trading at 9% of its 52-week range ($1.04 – $10.25). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
U.S. FDA clears IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria; additional Phase 2 studies planned in food allergy and relapsing multiple sclerosisCompany expands pipeline through research collaboratio
https://www.sec.gov/ix?doc=/Archives/edgar/data/1533743/000114036126041116/ef20084530_8k.htm
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical-stage pharmaceutical company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PCSA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PCSA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Processa Pharmaceuticals Inc. (PCSA) ranks #398 by composite RQD confidence (48/100, grade D) and #941 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, PCSA leads on earnings valuation at N/A trailing P/E, while PCSA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with PCSA at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PCSA
ACTIVE
Processa Pharmaceuticals Inc. | D | 48/100 | — | — | -35.0% | +2.16% | $5.3M | Benchmark Subject |
| PULM Pulmatrix Inc. | D- | 36/100 | — | — | -35.0% | -5.67% | $5.2M | /pulm-vs-pcsa → |
| GELS Gelteq Limited | C- | 59/100 | — | — | — | +5.11% | $5.4M | /gels-vs-pcsa → |
| BGMS Bio Green Med Solution Inc. | D- | 40/100 | — | — | -35.0% | -9.79% | $5.5M | /bgms-vs-pcsa → |
| CANF Can-Fite Biopharma Ltd each representing two (2) | E | 31/100 | — | — | -35.0% | +0.61% | $5.0M | /canf-vs-pcsa → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Processa Pharmaceuticals Inc. (PCSA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.6M, operating cash flow of -$11.4M, and free cash flow of -$11.4M (-1.2% YoY). On the balance sheet, PCSA closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$13.6M | -$11.4M | -$11.4M | $7.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$11.8M | -$11.2M | -$11.2M | $3.2M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$11.1M | -$8.1M | -$8.1M | — | — |
As of 2026-11-01, Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $1.89 (+2.16% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PCSA ranks #398 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PCSA carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PULM (Pulmatrix Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.2M) and GELS (Gelteq Limited) posts a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $5.4M). Among the 5-stock peer group, PCSA leads on earnings multiple (N/A) while PCSA leads on capital efficiency (-35.0% ROIC).
Per PCSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533743), Processa Pharmaceuticals Inc. generated $0 in revenue, -$13.6M in net income, and -$11.4M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PCSA last traded at $1.89 (+2.16% on volume of 104,812 shares), positioning the stock +2.16% above its 50-day simple moving average ($1.85) and -19.92% below its 200-day simple moving average ($2.36). Across its 52-week range of $1.04 to $10.25, PCSA sits at the 9.2% percentile with a 14-day RSI of 55.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.65 to $2.13).
Why PCSA Stock surged +2.16% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.